Cooper Financial Group’s Matinas BioPharma MTNB Stock Holding History

Cooper Financial Group’s Portfolio MTNB Stock Details MTNB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-278	Closed	-$3.01K	–	364
2023 Q4	$3.01K	Hold	278	–	–	﹤0.01%	342
2023 Q3	$1.81K	Hold	278	–	–	﹤0.01%	324
2023 Q2	$5K	Hold	278	–	–	﹤0.01%	316
2023 Q1	$6.53K	Hold	278	–	–	﹤0.01%	295
2022 Q4	$6.95K	Hold	278	–	–	﹤0.01%	291
2022 Q3	$9K	Buy	+278	New	+$10.9K	﹤0.01%	259

Other funds holding MTNB

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

SIG

Sargent Investment Group Bethesda, Maryland $759M AUM 28.58% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

AWA

Arkadios Wealth Advisors Atlanta, Georgia $6.13B AUM 23.41% 1-Year Est. Return

NRS

Neville Rodie & Shaw New York $1.55B AUM 46.95% 1-Year Est. Return

JEST

JTC Employer Solutions Trustee St Helier, Jersey $1.2B AUM 37.55% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

LPL Financial San Diego, California $377B AUM 19.32% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Cooper Financial Group's MTNB Position: Q1 2024 in Review

Cooper Financial Group sold out of Matinas BioPharma (MTNB) in Q1 2024, closing a stake of 278 shares — an estimated $3.01K sold.

Cooper Financial Group first reported a position in MTNB in Q3 2022 and held it in 6 quarters. The position peaked at $9K in Q3 2022. 42 funds tracked by Wall St. Rank hold MTNB as of Q1 2024.

Cooper Financial Group reported no remaining Matinas BioPharma position as of Q1 2024 after selling out during the quarter.
Cooper Financial Group sold 278 Matinas BioPharma shares in Q1 2024, an estimated $3.01K.
Cooper Financial Group first reported a position in Matinas BioPharma in Q3 2022 and held it in 6 quarters.
Cooper Financial Group's Matinas BioPharma position peaked at $9K in Q3 2022.
42 funds tracked by Wall St. Rank held Matinas BioPharma as of Q1 2024.

Based on Cooper Financial Group's 13F filing for Q1 2024, filed 11 Apr 2024.